Rachel Schmidtberger, MD
Dermatology · Katy, TXNPI 1487074746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 750 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations.
Across 750 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$2K
- Lilly USA, LLC$877
- Johnson & Johnson$801
- Mayne Pharma Commercial LLC$800
- Sanofi$584
- plus $5K from 23 others
What the payments were for
- Food & beverage$11,20096%
- Education$4854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 128 | $2,085 |
| Novartis | 169 | $1,844 |
| Lilly USA, LLC | 50 | $877 |
| Johnson & Johnson | 28 | $801 |
| Mayne Pharma Commercial LLC | 117 | $800 |
| Sanofi | 21 | $584 |
| Arcutis Biotherapeutics, Inc. | 30 | $540 |
| Sun Pharmaceutical Industries Inc. | 19 | $503 |
| Regeneron Healthcare Solutions, Inc. | 18 | $502 |
| E.r. Squibb & Sons, L.L.C. | 24 | $483 |
| Pfizer | 24 | $445 |
| UCB, Inc. | 14 | $340 |
| Dermavant Sciences, Inc. | 24 | $311 |
| LEO Pharma Inc. | 16 | $308 |
| Galderma Laboratories, L.p. | 15 | $225 |
| Amgen | 10 | $218 |
| Incyte Corporation | 10 | $218 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $147 |
| EPI Health, LLC | 4 | $82 |
| Bristol Myers Squibb | 4 | $67 |
| Biocon Biologics Inc | 3 | $60 |
| Springworks Therapeutics, Inc. | 2 | $58 |
| Almirall LLC | 2 | $42 |
| Boehringer Ingelheim | 2 | $40 |
| Biofrontera Inc. | 3 | $38 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Organon | 2 | $18 |
| DUSA Pharmaceuticals, Inc. | 1 | $17 |
| Encore Dermatology Inc. | 1 | $15 |
How this compares
$11,684 in reported general payments places this provider in the 75th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 11 | $222,297 |
| Dupixent PenDupilumab | 12 | $48,297 |
| Clobetasol Propionate | 105 | $9,195 |
| Fluorouracil | 127 | $8,879 |
| Ketoconazole | 214 | $2,606 |
| Fluocinonide | 64 | $2,238 |
| Triamcinolone Acetonide | 239 | $1,910 |
| Doxycycline Monohydrate | 80 | $1,822 |
| Clindamycin Phosphate | 37 | $1,442 |
| Metronidazole | 37 | $1,412 |
| Betamethasone Dipropionate | 24 | $1,363 |
| Ciclopirox | 28 | $828 |
| Minoxidil | 60 | $656 |
| Fluconazole | 59 | $517 |
| Nystatin | 45 | $491 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Katy
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- Daniel CarrascoAustin$1.1M
- Dale SchaeferAustin$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.